J. Marshall

发表

The current state of molecular testing in the treatment of patients with solid tumors, 2019

Edward S. Kim, W. El-Deiry, R. Goldberg, 2019, CA: a cancer journal for clinicians.

Recurrence of Early Stage Colon Cancer Predicted by Expression Pattern of Circulating microRNAs

Subha Madhavan, Louis M. Weiner, Anton Wellstein, 2014, PloS one.

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

M. Gilbert, M. Kris, E. Basch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss

J. Marshall, I. Wainer, P. Bhargava, 2001, British Journal of Cancer.

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

R. Schilsky, J. Marshall, P. Rougier, 2004, British Journal of Cancer.

βII‐Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin

Y. Gusev, S. Byers, J. Marshall, 2015, Hepatology.

Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse

S. Madhavan, Y. Gusev, S. Byers, 2013, Front. Genet..

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

M. Ratain, J. Marshall, N. Rizvi, 2004, Investigational New Drugs.

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Seta Shahin, J. Hecht, J. Marshall, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment

J. Marshall, A. Fu, A. Potosky, 2016, Journal of Cancer Research and Clinical Oncology.

Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors.

Edward S. Kim, P. Philip, R. Goldberg, 2018 .

Liquid biopsies and cancer omics

I. Amelio, G. Melino, J. Marshall, 2020, Cell death discovery.

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.

R. Schilsky, E. Van Cutsem, J. Marshall, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

Suzanne F. Jones, J. Marshall, H. Burris, 2010, Clinical Cancer Research.

Vaccines for the Treatment of Cancer

J. Marshall, J. Gulley, P. Arlen, 2004 .

A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.

J. Marshall, W. Dahut, B. Dvorchik, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer.

W. Hong, J. Marshall, N. Rizvi, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel vaccines for the treatment of gastrointestinal cancers.

J. Marshall, 2005, Oncology.

Costimulatory molecules as adjuvants for immunotherapy.

J. Marshall, J. Schlom, H. Sabzevari, 2006, Frontiers in bioscience : a journal and virtual library.

Risk assessment in Stage II colorectal cancer.

J. Marshall, 2010, Oncology.

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

J. Berlin, A. Oza, J. Marshall, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors

C. Rudin, M. Ratain, J. Marshall, 2004, Clinical Cancer Research.

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

C. Fuchs, J. Marshall, V. Ganju, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.

C. Fuchs, J. Marshall, J. Barrueco, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine

A. Shields, J. Marshall, M. Zalupski, 2004, Cancer.

Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer.

J. Marshall, M. Al-Hajeili, B. Smaglo, 2016, Oncology.

Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study.

J. Marshall, Hongkun Wang, M. Pishvaian, 2014, Gastrointestinal cancer research : GCR.

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies

J. Marshall, Hongkun Wang, M. Pishvaian, 2015, Cancer.

Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies.

J. Marshall, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents

J. Marshall, M. Pishvaian, Christina Wu, 2010, Gastrointestinal cancer research : GCR.

Optimum use of biologics and role of maintenance therapy in colon cancer.

J. Marshall, 2006, Seminars in oncology.

Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.

J. Marshall, B. Glimelius, A. de Gramont, 2021, Cancer treatment reviews.

Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.

J. Marshall, Jimmy J. Hwang, S. Eisenberg, 2003, Oncology.

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.

N. Wolmark, R. Goldberg, J. Marshall, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer.

J. Marshall, S. Kopetz, A. Pereira, 2019, The oncologist.

How much is enough: 3 versus 6 months of adjuvant therapy for colon cancer

J. Marshall, 2017 .

Accomplishments in 2008 in the adjuvant treatment of colon cancer.

J. Marshall, C. Köhne, A. de Gramont, 2009, Gastrointestinal cancer research : GCR.

Managing potentially resectable metastatic colon cancer.

J. Marshall, 2008, Gastrointestinal cancer research : GCR.

How to incorporate a chemo-free interval into the management of metastatic colorectal cancer.

J. Marshall, A. Grothey, F. Ciardiello, 2020, Clinical advances in hematology & oncology : H&O.

Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit

R. Yarden, J. Marshall, B. Weinberg, 2020, Colorectal Cancer.

A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC 1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer

Anuradha, J. Marshall, D. Hsu, 2013 .

A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer

J. Marshall, D. Hsu, T. Crocenzi, 2013, Annals of surgery.

Trifluridine/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer.

J. Marshall, M. Salem, B. Weinberg, 2016, Clinical advances in hematology & oncology : H&O.

Highlights From: 39th Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois May 31 to June 3, 2003

J. Marshall, E. Chu, H. Degrendele, 2003 .

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

G. Rosner, J. Byrd, M. Ratain, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Rechallenging 5-Fluorouracil in a Patient With Capecitabine-Induced Ventricular Fibrillation.

J. Marshall, Sueyi Lai, Richard Morrissey, 2015, Clinical colorectal cancer.

Safety of capecitabine: a review

J. Marshall, S. Mikhail, Jun F Sun, 2010, Expert opinion on drug safety.

Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers.

A. Noone, J. Marshall, R. Slack, 2009, Gastrointestinal cancer research : GCR.

Capecitabine: fulfilling the promise of oral chemotherapy

J. Marshall, Jimmy J. Hwang, J. Hwang, 2002, Expert opinion on pharmacotherapy.

Evaluation of Hypertension as a Marker of Bevacizumab Efficacy

A. Noone, J. Marshall, R. Slack, 2009, Journal of gastrointestinal cancer.

The role of bevacizumab as first-line therapy for colon cancer.

J. Marshall, 2005, Seminars in oncology.

Patients Living Longer With Metastatic Colorectal Cancer

J. Marshall, R. Sommers, Robin M. Sommers, 2016, Journal of the advanced practitioner in oncology.

Clinical Pharmacokinetics and Pharmacology of Trimetrexate

J. Marshall, R. Delap, R. DeLap, 1994, Clinical pharmacokinetics.

Maintenance therapy in metastatic colorectal cancer.

J. Marshall, 2014, Clinical advances in hematology & oncology : H&O.

Oral Fluoropyrimidines in Colorectal Cancer

J. Marshall, 2002 .

Is levoleucovorin an alternative to racemic leucovorin? A literature review.

J. Marshall, P. Kovoor, S. Karim, 2009, Clinical colorectal cancer.

Considerations in the management of younger patients with colorectal cancer.

J. Marshall, C. Eng, C. Cremolini, 2021, Clinical advances in hematology & oncology : H&O.

Cases in the management of metastatic colorectal cancer: use of regorafenib as a bridge to chemotherapy.

J. Marshall, 2021, Clinical advances in hematology & oncology : H&O.

Transitioning from second-line to third-line therapy in metastatic colorectal cancer.

J. Marshall, T. Bekaii-Saab, F. Loupakis, 2021, Clinical advances in hematology & oncology : H&O.

Current Options for Third-Line Treatment of Metastatic Colorectal Cancer.

J. Marshall, A. Grothey, T. Seery, 2016, Clinical advances in hematology & oncology : H&O.

Implementation of a performance improvement initiative in colorectal cancer care.

J. Marshall, T. Cartwright, C. Berry, 2012, Journal of oncology practice.

Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.

J. Marshall, 2008, Clinical colorectal cancer.

The current state of molecular profiling in gastrointestinal malignancies

J. Marshall, M. Kulasekaran, A. He, 2022, Biology direct.

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer

J. Marshall, T. Bekaii-Saab, M. Villalona-Calero, 2015, Scientific Reports.

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors

B. Sikic, J. Marshall, M. Pishvaian, 2012, Investigational New Drugs.

A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.

S. Steinberg, J. Marshall, J. Schlom, 2022, The oncologist.

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

J. Marshall, M. Uttenreuther-Fischer, H. Burger, 2012, Investigational New Drugs.

Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.

J. Marshall, M. Pishvaian, J. Deeken, 2015, Current cancer drug targets.

Neoadjuvant Combined-Modality Therapy for Locally Advanced Rectal Cancer and Its Future Direction.

J. Marshall, M. Salem, K. Unger, 2016, Oncology.

Phase I study of RX-0201 in patients with advanced or metastatic solid tumors.

J. Marshall, J. Hwang, J. Posey, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors

L. Ellis, S. Curley, H. Lenz, 2007 .

More fanfare for metastatic colon cancer resections.

J. Marshall, 2007, Gastrointestinal cancer research : GCR.

The development of novel agents for the treatment of colorectal cancer: a critical review of current practice and some suggestions for the future.

E. Gehan, J. Marshall, 2007, Clinical advances in hematology & oncology : H&O.

Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.

J. Marshall, A. Grothey, 2007, Oncology.

Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.

C. Rudin, J. Marshall, A. Dritschilo, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

G. Ciliberto, J. Marshall, N. La Monica, 2013, Journal of Translational Medicine.

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

J. Marshall, R. Kurzrock, P. Munster, 2014, Cancer Chemotherapy and Pharmacology.

Current State of Targeted Therapy and Immunotherapy in Advanced Gastric and Gastro-oesophageal Cancers

J. Marshall, M. Noel, Chao Yin, 2022, Oncology & Haematology.

A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors

J. Marshall, M. Ernstoff, N. Vogelzang, 2011, Journal of immunotherapy.

A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.

J. Marshall, D. Flockhart, M. Williams, 2000, British journal of clinical pharmacology.

Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC

M. Atkins, F. Banovac, J. Marshall, 2016, Cancer Immunology Research.

The clinical experience with antiangiogenic agents

J. Marshall, M. Hawkins, 2004, Breast Cancer Research and Treatment.

Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics

J. Marshall, R. Slack, J. Deeken, 2008, Cancer.

Molecular characterization of squamous cell carcinoma of the anal canal (SCCA).

P. Philip, W. El-Deiry, H. Lenz, 2017 .

This is a repository copy of Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B

D. Sargent, C. Bokemeyer, J. Marshall, 2019 .

Colorectal cancer: Impact of primary tumor location on genetic alterations.

P. Philip, H. Lenz, A. Shields, 2017 .

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.

J. Marshall, J. Schlom, R. Slack, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Relationship Between a Urinary Cachectic Factor and Weight Loss in Advanced Cancer Patients

J. Marshall, L. Brant, M. Williams, 2004, Cancer investigation.

Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.

J. Marshall, J. Schlom, E. Richmond, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.

E. Gehan, J. Marshall, J. Schlom, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors.

J. Marshall, A. He, B. Singh, 2019, The oncologist.

Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers.

P. Philip, R. Goldberg, H. Lenz, 2019, Journal of Clinical Oncology.

Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer

P. Philip, R. Goldberg, H. Lenz, 2019, Clinical Cancer Research.

Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).

P. Philip, A. Barzi, R. Goldberg, 2018 .

A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies

J. Marshall, Hongkun Wang, M. Pishvaian, 2021, Cancer medicine.

KRN330, a fully human antibody against A33, in combination with irinotecan for patients with metastatic colorectal cancer (mCRC).

J. Berlin, J. Marshall, J. Bendell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer

J. Marshall, S. Kim-Schulze, H. Kaufman, 2007, Journal of Translational Medicine.

Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology.

J. Ajani, P. Philip, R. Goldberg, 2007, Gastrointestinal cancer research : GCR.

A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.

J. Marshall, J. Schlom, J. Gulley, 2003, Journal of immunological methods.

Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.

J. Marshall, N. Rizvi, Jimmy J. Hwang, 2003, Oncology.

Initial results from ongoing phase I trials of a novel pan bcl-2 family small molecule inhibitor

B. Cheson, J. Marshall, P. Lebowitz, 2005 .

Chemotherapy in Patients with Organ Dysfunction

J. Marshall, Jimmy J. Hwang, S. Malik, 2006 .

Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets

P. Philip, R. Goldberg, H. Lenz, 2022, Oncogene.

Relationship between MLH1, PMS2, MSH2 and MSH6 gene‐specific alterations and tumor mutational burden in 1057 microsatellite instability‐high solid tumors

Edward S. Kim, R. Goldberg, H. Lenz, 2020, International journal of cancer.

Molecular Characterization of Appendiceal Goblet Cell Carcinoid

P. Philip, R. Goldberg, H. Lenz, 2020, Molecular Cancer Therapeutics.

A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma.

J. Marshall, M. Morse, D. Cole, 2006, Clinical colorectal cancer.

A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma

J. Marshall, L. Weiner, Hongkun Wang, 2019, Journal of pancreatic cancer.

A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer.

P. Philip, J. Marshall, E. Lin, 2012, Gastrointestinal cancer research : GCR.

A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

J. Marshall, Hongkun Wang, M. Pishvaian, 2020, Journal of pancreatic cancer.

Ginkgo Biloba (GB) extract as a neuroprotective agent in oxaliplatin (Ox)-induced neuropathy.

J. Marshall, J. Hwang, V. Papadopoulos, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss

J. Marshall, I. Wainer, P. Bhargava, 2001, British Journal of Cancer.

Targeted therapy for colorectal cancer.

J. Marshall, Jimmy J. Hwang, J. Hwang, 2006, Current opinion in investigational drugs.

A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.

J. Marshall, R. Cohen, N. Lewis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical and clinical experience with cisplatin resistance.

J. Marshall, P. Andrews, Paul A. Andrews, 1995, Hematology/oncology clinics of North America.

Immediate impact of the FOLFIRINOX phase III data reported at the 2010 ASCO Annual Meeting on prescribing plans of American oncology physicians for patients with metastatic pancreas cancer (MPC).

J. Marshall, J. Bendell, M. Green, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular profile of BRCA-mutated biliary tract cancers

P. Philip, W. El-Deiry, R. Goldberg, 2020, ESMO Open.

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors

L. Hartmann, J. Marshall, L. Alland, 2015, Investigational New Drugs.

A phase I study of oral ixabepilone in patients with advanced solid tumors

J. Marshall, P. LoRusso, M. Pishvaian, 2014, Cancer Chemotherapy and Pharmacology.

The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.

R. Salazar, J. Marshall, R. Rosenberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

J. Berlin, H. Lenz, J. Marshall, 2018, British Journal of Cancer.

A pilot study of molecularly tailored therapy for patients with metastatic pancreatic cancer (MPC).

J. Marshall, L. Weiner, Hongkun Wang, 2015 .

A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer

J. Marshall, J. Posey, Jimmy J. Hwang, 2007 .

Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer

J. Marshall, R. Dickson, J. Low, 2004, Investigational New Drugs.

A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer

J. Marshall, H. Hurwitz, N. Rizvi, 2004, Clinical Cancer Research.

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.

Michael R. Lindberg, R. Holcombe, A. Shields, 2019, Journal of gastrointestinal oncology.

Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

J. Verweij, J. Marshall, J. Gietema, 2005 .

TNM staging of pancreatic carcinoma using helical CT.

P. Silverman, A. Zeiberg, R. Zeman, 1997, AJR. American journal of roentgenology.

Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells

J. Marshall, H. Juhl, M. Walker, 2002, Oncogene.

An open-label, multi-center, phase 2 study of switch maintenance with TAS-102 plus bevacizumab following oxaliplatin or irinotecan-based fluoropyrimidine-containing induction chemotherapy in patients with metastatic colorectal cancer: ALEXANDRIA study.

J. Marshall, M. Fakih, T. Bekaii-Saab, 2016 .

A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion.

M. Berger, J. Marshall, M. Pishvaian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 trial of GMX1777: An inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT)

M. Berger, J. Marshall, M. Pishvaian, 2008 .

A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C).

C. Fuchs, J. Marshall, V. Ganju, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies

J. Marshall, G. Weiss, M. Pishvaian, 2013, Cancer Chemotherapy and Pharmacology.

Capecitabine in colorectal cancer.

J. Marshall, 2001, Oncology.

Bevacizumab in the treatment of colorectal cancer.

J. Marshall, 2007, Clinical advances in hematology & oncology : H&O.

Propagated circulating tumor cells uncovers the role of NFκB and COP1 in metastasis

J. Marshall, H. Goodarzi, M. Lippman, 2022, bioRxiv.

Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.

J. Marshall, E. Richmond, R. Delap, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Carcinoembryonic antigen-based vaccines.

J. Marshall, 2003, Seminars in oncology.

Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.

P. Philip, R. Goldberg, H. Lenz, 2018, The oncologist.

A Phase I study of LGD1069 in adults with advanced cancer.

J. Marshall, N. Rizvi, W. Dahut, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Metastatic unresectable colorectal cancer: is the cost of treatment justified?

J. Marshall, 2016 .

A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies

G. Giaccone, J. Marshall, L. Weiner, 2018, Cancer Chemotherapy and Pharmacology.

A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.

J. Marshall, N. Rizvi, W. Dahut, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pancreatic cancer, treatment options, and GI-4000

J. Marshall, N. Bade, Marion L Hartley, 2015, Human vaccines & immunotherapeutics.

Evaluating the impact of age on immune checkpoint therapy biomarkers

A. Weeraratna, E. Jaffee, C. Isaacs, 2021, Cell Reports.

Immunologic therapies for gastrointestinal cancers.

J. Marshall, B. Levy, J. Deeken, 2005, Clinical colorectal cancer.

Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology.

J. Ajani, R. Goldberg, H. Lenz, 2007, Gastrointestinal cancer research : GCR.

Phase I S tudy i n C ancer P atients o f a R eplication-Defe ctive Avipox R ecombinant V accine T hat E xpresses H uman Carcinoembryonic A ntigen

J. Marshall, J. Schlom, E. Richmond, 1999 .

Clinical experiences with G17DT in gastrointestinal malignancies

J. Marshall, A. He, 2006, Expert review of anticancer therapy.

Vaccine Therapy for Gastrointestinal Cancers

J. Marshall, 2004 .

COLORECTAL CANCER Targeted Therapy and the Use of Molecular Profiling in Metastatic Colorectal Cancer

H. Wakelee, J. Marshall, M. Pishvaian, 2017 .

Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.

J. Marshall, A. He, Christine C Hsu, 2019, The oncologist.

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Colin C. Pritchard, James L. Gulley, John M. Kirkwood, 2018, Journal of Immunotherapy for Cancer.

Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers

P. Philip, R. Goldberg, H. Lenz, 2021, Molecular Cancer Therapeutics.

Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.

John L Marshall, C. Isaacs, J. Marshall, 2018, JCO precision oncology.

Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer

P. Philip, R. Goldberg, H. Lenz, 2021, Oncogene.

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers

John L Marshall, P. Philip, R. Goldberg, 2018, Molecular Cancer Research.

Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors.

P. Philip, R. Goldberg, H. Lenz, 2018, The oncologist.

Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.

A. Shields, J. Marshall, M. Salem, 2018, The oncologist.

Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients

J. Marshall, N. Xiao, Z. Gatalica, 2018, Cancer medicine.

WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype

R. Goldberg, H. Lenz, A. Shields, 2020, Cancers.

Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

Lillian L. Siu, David Mendelson, Michael J. Pishvaian, 2010, Clinical Cancer Research.

A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies

G. Demetri, J. Marshall, M. Pishvaian, 2012, Cancer.

Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer.

J. Marshall, N. Rizvi, E. Ulm, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer

G. Mills, J. Marshall, R. Broaddus, 2021, Clinical Cancer Research.

Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.

Sridhar Ramaswamy, Daniel J Sargent, Oliver F Bathe, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer

J. Marshall, A. Wellstein, L. Weiner, 2016, Oncology letters.

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.

R. Labianca, D. Kerr, K. Haustermans, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies.

G. Demetri, J. Marshall, M. Pishvaian, 2010 .

Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type

M. Oberley, P. Stafford, E. Heath, 2021, Translational oncology.

Preoperative evaluation and treatment of rectal cancer

J. Marshall, Zheng Wu, 2010 .

Metastatic Colorectal Cancer

E. Warner, J. Marshall, J. Desai, 2019, Textbook of Gastrointestinal Oncology.

Stem Cells in Gastrointestinal Cancers

J. Marshall, L. Mishra, J. Mendelson, 2008, Disease markers.

The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

P. Stafford, R. Goldberg, H. Lenz, 2021, Clinical Cancer Research.

Molecular Variances Between Right- and Left-sided Colon Cancers

J. Marshall, M. Salem, A. Puccini, 2018, Current Colorectal Cancer Reports.

Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer

D. Berry, M. Oberley, P. Stafford, 2020, Clinical Cancer Research.

The impact of ARID1A mutation on molecular characteristics in colorectal cancer.

P. Philip, R. Goldberg, H. Lenz, 2020, European journal of cancer.

Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer.

R. Goldberg, H. Lenz, A. Shields, 2019, The oncologist.

Biomarkers for immune therapy in gastrointestinal cancers.

J. Marshall, B. Weinberg, R. Hameed, 2019, Clinical advances in hematology & oncology : H&O.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

D. Sargent, C. Bokemeyer, E. Van Cutsem, 2018, European journal of cancer.

Targeted Therapy and the Use of Molecular Profiling in Metastatic Colorectal Cancer

J. Marshall, G. Brar, and Michael J. Pishvaian, 2017 .

Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers

P. Philip, W. El-Deiry, H. Lenz, 2017, Oncotarget.

Neoadjuvant Chemoradiotherapy and Neoadjuvant Chemotherapy

J. Marshall, M. Salem, 2018 .

Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives

J. Marshall, A. Seeber, Reetu Mukherji, 2020, Cancers.

A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer

J. Marshall, L. Weiner, M. Pishvaian, 2018, Cancer.

Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes

Edward S. Kim, P. Stafford, H. Lenz, 2021, Scientific Reports.

Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium.

E. Diamandis, J. Marshall, G. Sardana, 2007, Clinical chemistry.

A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.

J. Marshall, D. Hayes, M. Lippman, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD.

G. Pinkus, M. Shipp, D. Rosenthal, 1986, Annals of internal medicine.

Maintenance therapy in solid tumors

J. Marshall, M. Smit, 2012 .

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

J. Marshall, N. Rizvi, W. Figg, 2002, Journal of experimental therapeutics & oncology.

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.

M. Oberley, P. Stafford, H. Lenz, 2021, Journal of the National Cancer Institute.

Future of targeted agents in metastatic colorectal cancer.

M. Burotto, J. Marshall, M. Pishvaian, 2012, Colorectal cancer.

The Essentials of Multiomics

C. Haudenschild, D. Kerr, G. Melino, 2022, The oncologist.

Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.

J. Hanfelt, J. Marshall, A. Wellstein, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer

J. Marshall, L. Weiner, Hongkun Wang, 2020, Clinical Cancer Research.

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

W. Hayes, D. Nuyten, J. Marshall, 2011, British Journal of Cancer.

Biologic therapies for advanced pancreatic cancer

J. Marshall, A. He, A. Lindenberg, 2008, Expert review of anticancer therapy.

Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma

P. Philip, H. Lenz, A. Shields, 2020, Journal of surgical oncology.

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.

H. Lenz, J. Marshall, H. Hurwitz, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.

J. Marshall, E. Chu, H. Degrendele, 2003, Clinical colorectal cancer.

Conference Scene: Fighting a smarter war against cancer

J. Marshall, 2014 .

Discordance of KRAS mutational status in a single colonic resection specimen in a patient with colorectal cancer: a case report and review of the literature.

J. Marshall, B. Smaglo, 2013, Clinical colorectal cancer.

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.

G. Shapiro, J. Marshall, M. Uttenreuther-Fischer, 2013, Future oncology.

Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States

J. Marshall, J. Signorovitch, O. Patterson-Lomba, 2018, Advances in Therapy.

Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma

J. Marshall, L. Weiner, M. Pishvaian, 2014, American journal of clinical oncology.

Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer

J. Marshall, L. Weiner, M. Pishvaian, 2015, Cancer Chemotherapy and Pharmacology.

Pancreatic cancer, treatment options, and GI-4000

J. Marshall, N. Bade, Marion L Hartley, 2014, Human vaccines & immunotherapeutics.

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012

R. Labianca, M. Büchler, J. Berlin, 2013 .

Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety

J. Marshall, M. Pishvaian, G. Tse, 2013, Radiation oncology.

Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma.

P. Stafford, P. Philip, W. El-Deiry, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Enrichment of alterations in targetable molecular pathways in KRAS wild-type (WT) pancreatic cancer (PC).

P. Philip, A. Shields, J. Marshall, 2020 .

Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)

P. Philip, A. Barzi, R. Goldberg, 2020, Clinical Cancer Research.

The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling

L. Lin, J. Marshall, L. Mishra, 2009, Oncogene.

Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

J. Marshall, 2006, Cancer.

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.

J. Marshall, N. Rizvi, D. Sterman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance therapy for colorectal cancer.

J. Marshall, 2014, Oncology.

Cancer predictive studies

I. Amelio, G. Melino, J. Marshall, 2020, Biology direct.

Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer

J. Marshall, M. Pishvaian, M. Gurka, 2018, Journal of Gastrointestinal Cancer.

Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.

A. Chen, K. Shilo, J. Marshall, 2016, Journal of the National Cancer Institute.

Peritoneal metastases from primary appendiceal and colorectal carcinomas demonstrate distinct molecular identities on comprehensive tumor analysis

B. Somer, P. Philip, H. Lenz, 2023, Journal of surgical oncology.

M. Burotto, J. Marshall, B. Haddad, 2013, World journal of gastrointestinal oncology.

Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors.

J. Marshall, A. He, B. Singh, 2020 .

Phase II Trial of Docetaxel Chemotherapy in Patients with Incurable Adenocarcinoma of the Esophagus

S. Piantadosi, E. Heath, J. Marshall, 2002, Investigational New Drugs.

A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC).

J. Marshall, L. Weiner, Hongkun Wang, 2013 .

The Growing Challenge of Young Adults With Colorectal Cancer.

J. Marshall, M. Salem, B. Weinberg, 2017, Oncology.

P3-112: Initial phase 1 results of gemcitabine, carboplatin and IMO-2055, a toll like receptor 9 (TLR9) agonist, in patients (pts) with advanced solid tumors

R. Karr, J. Marshall, S. Malik, 2007 .

Biologic therapy for colon cancer.

J. Marshall, A. He, 2005, Clinical advances in hematology & oncology : H&O.

Carcinoembryonic antigen as a vaccine target

J. Marshall, D. Wang, S. Rayani, 2008, Expert review of vaccines.

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

S. Steinberg, A. Chen, J. Marshall, 2000, Cancer Immunology, Immunotherapy.

TRICOM: enhanced vaccines as anticancer therapy

J. Marshall, B. Levy, Dennis L Panicalli, 2004, Expert review of vaccines.

Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer

A. Benson, H. Lenz, J. Marshall, 2008, Clinical Cancer Research.

Phase I Study of Prolonged Infusion Bryostatin-1 in Patients

J. Marshall, N. Rizvi, Michael D. Johnson, 2002, Cancer biology & therapy.

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

J. Berlin, R. Goldberg, J. Marshall, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma

J. Marshall, Xue Wang, Yunan Wu, 2021, Theranostics.

A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.

J. Marshall, K. Holroyd, W. Dahut, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I and pharmacokinetic (PK) study of docetaxel (DOC) and oxaliplatin (OX)

J. Marshall, W. Zamboni, S. Malik, 2005 .

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma

P. Philip, W. El-Deiry, R. Goldberg, 2020, ESMO Open.

Tissue and Serum microRNAs in the KrasG12D Transgenic Animal Model and in Patients with Pancreatic Cancer

J. Marshall, A. Wellstein, A. Riegel, 2011, PloS one.

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.

J. Marshall, R. Dickson, H. Rasmussen, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.

A. Barzi, H. Lenz, J. Marshall, 2021, Journal of Clinical Oncology.

Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic

J. Marshall, Reetu Mukherji, 2021, Current Treatment Options in Oncology.

Mass spectrometry: uncovering the cancer proteome for diagnostics.

Katerina Oikonomopoulou, E. Diamandis, J. Marshall, 2007, Advances in cancer research.

A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.

J. Hanfelt, J. Marshall, Michael D. Johnson, 2004, Clinical colorectal cancer.

Approach to the medical management of surgically resectable gastric cancer.

J. Marshall, B. Smaglo, Anteneh A. Tesfaye, 2016, Clinical advances in hematology & oncology : H&O.

Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.

G. Giaccone, J. Marshall, A. Wellstein, 2018, Cancer genetics.

Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.

G. Giaccone, J. Marshall, A. Wellstein, 2017, Cancer Genetics.

KRAS and extended RAS molecular profiling in metastatic colorectal cancer

J. Marshall, Sueyi Lai, Jaydeep Kachhela, 2014 .

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.

K. Owzar, M. Ratain, M. Edelman, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and gemcitabine combinations in non-small cell lung cancer.

J. Marshall, N. Rizvi, W. Dahut, 1999, Seminars in Oncology.

Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC).

J. Marshall, L. Weiner, Hongkun Wang, 2019, Journal of Clinical Oncology.

Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors

J. Nemunaitis, J. Marshall, T. Bekaii-Saab, 2016, Targeted Oncology.

Colon Cancer in Young Adults: Trends and Their Implications

J. Marshall, B. Weinberg, 2019, Current Oncology Reports.

Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer

J. Berlin, T. Ryan, H. Lenz, 2014, Investigational New Drugs.

Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?

J. Marshall, M. Carducci, 2009, Journal of oncology.

Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients >65 years compared with those ≤65: The BICC-C study

C. Fuchs, J. Marshall, V. Ganju, 2007 .

Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.

M. Oberley, H. Lenz, A. Shields, 2023, The Lancet. Oncology.

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.

M. Oberley, H. Lenz, A. Shields, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

The landscape of POLE variants in colorectal and endometrial tumors: Correlation with microsatellite instability (MSI) and tumor mutation burden (TMB).

R. Goldberg, A. Shields, J. Marshall, 2020 .

Molecular variances between rectal and left-sided colon cancers.

P. Philip, W. El-Deiry, H. Lenz, 2017 .

Comparative molecular analyses of colon versus rectal tumors.

P. Philip, W. El-Deiry, A. Shields, 2016 .

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.

G. Lesinski, J. Marshall, T. Bekaii-Saab, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies.

J. Marshall, J. Posey, U. Verma, 1999, Journal of immunotherapy.

Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).

J. Nemunaitis, J. Marshall, R. Finn, 2017 .

Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs).

Edward S. Kim, R. Goldberg, H. Lenz, 2019, Journal of Clinical Oncology.

Sequencing beyond the second-line setting in metastatic colorectal cancer.

J. Marshall, A. Grothey, T. Bekaii-Saab, 2019, Clinical advances in hematology & oncology : H&O.

A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer.

J. Marshall, M. Salem, B. Weinberg, 2016, Clinical advances in hematology & oncology : H&O.

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer

E. Gehan, J. Hanfelt, J. Marshall, 2001, Cancer Chemotherapy and Pharmacology.

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma

J. Marshall, Hongkun Wang, M. Pishvaian, 2015, Cancer Chemotherapy and Pharmacology.

A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors.

J. Marshall, M. Pishvaian, B. Collins, 2011, Clinical lung cancer.

Challenges That Hinder the Translation of Clinical Advances Into Practice: Results From an International Assessment in Colorectal Cancer.

J. Marshall, S. Murray, P. Lazure, 2016, Clinical colorectal cancer.

Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling.

A. Biankin, J. Marshall, D. Chang, 2019, Chinese clinical oncology.

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes

D. Berry, R. Greil, John Quackenbush, 2018, Nature Communications.

Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and COP1 in Metastasis

J. Marshall, H. Goodarzi, M. Lippman, 2023, Cancers.

A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies

E. Petricoin, J. Marshall, Hongkun Wang, 2019, Cancer Chemotherapy and Pharmacology.

Time to shift the focus of the war: it is not all about the enemy.

J. Marshall, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of tumor mutation load (TML) in solid tumors.

Edward S. Kim, M. Atkins, P. Philip, 2017 .

Comparing safety and efficacy of first‐line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer

J. Meyerhardt, J. Marshall, E. Mitchell, 2009, Cancer.

Phase II trial of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma (HCC).

J. Marshall, L. Weiner, Hongkun Wang, 2014 .

A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer.

J. Marshall, L. Weiner, M. Pishvaian, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic Therapy for Colorectal Cancer Liver Metastases: Sorting Through the Options

J. Marshall, Sunnie S. Kim, B. Singh, 2019 .

An alternate method to overcoming central venous catheter blockage in patients receiving high-dose fluorouracil and leucovorin.

J. Marshall, R. Delap, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study

J. Marshall, A. Figer, P. Karásek, 2005 .

Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer

Z. Trajanoski, R. Goldberg, H. Lenz, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of the pan-Bcl2 family inhibitor GX15-070, administered as a 3-hour weekly infusion in patients with refractory solid tumors or lymphomas.

J. Marshall, L. Siu, J. Kuruvilla, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: Updated efficacy data

C. Fuchs, J. Marshall, V. Ganju, 2007 .

Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.

J. Marshall, T. Crocenzi, D. Niedzwiecki, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment

Subha Madhavan, Shruti Rao, Robert A. Beckman, 2016, Oncotarget.

A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy

Rebecca Slack, John Deeken, Merrill J. Egorin, 2012, Cancer Chemotherapy and Pharmacology.

Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer

J. Marshall, A. Wellstein, M. Pishvaian, 2013, International Journal of Colorectal Disease.

Molecular characterization of appendiceal goblet cell carcinoid.

P. Philip, R. Goldberg, H. Lenz, 2020 .

Safety profile of therapeutic pox virus-based vaccines for cancer.

R. DiPaola, J. Marshall, J. Schlom, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.

J. Marshall, J. Warren, A. Freedman, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.

P. Philip, W. El-Deiry, R. Goldberg, 2019, Journal of Clinical Oncology.

Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation.

J. Marshall, R. Pestell, M. Liu, 2004, Current cancer drug targets.

Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets

R. Goldberg, H. Lenz, A. Shields, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy

J. Marshall, A. Freedman, A. Fu, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

The Ruesch Center Symposium 2014: Fighting a Smarter War against Cancer Using Immunotherapy

J. Marshall, Marion L Hartley, 2015 .

Comprehensive molecular profiling of IDH1/2 mutant biliary cancers (BC).

R. Goldberg, H. Lenz, A. Shields, 2020 .

A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy

G. Giaccone, J. Marshall, P. LoRusso, 2007 .

Pulse dose imatinib (Im) and weekly paclitaxel (P) phase I trial for advanced refractory solid tumors

J. Marshall, K. McDougall, M. Egorin, 2005 .

Novel panomic validation of time to next treatment (TNT) as an effective surrogate outcome measure in 4,729 patients.

Edward S. Kim, G. Bepler, W. El-Deiry, 2016 .

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Lindsay A. Renfro, Herbert I. Hurwitz, L. Diaz, 2017, Clinical Cancer Research.